These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26138622)

  • 1. Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery.
    Powell G; Holmes EA; Plumpton CO; Ring A; Baker GA; Jacoby A; Pirmohamed M; Marson AG; Hughes DA
    Br J Clin Pharmacol; 2015 Nov; 80(5):1149-59. PubMed ID: 26138622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy.
    Plumpton CO; Yip VL; Alfirevic A; Marson AG; Pirmohamed M; Hughes DA
    Epilepsia; 2015 Apr; 56(4):556-63. PubMed ID: 26046144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment.
    Lloyd A; McIntosh E; Price M
    Pharmacoeconomics; 2005; 23(11):1167-81. PubMed ID: 16277551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma.
    Mühlbacher AC; Nübling M
    Eur J Health Econ; 2011 Jun; 12(3):193-203. PubMed ID: 20107856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient versus neurologist preferences: A discrete choice experiment for antiepileptic drug therapies.
    Ettinger AB; Carter JA; Rajagopalan K
    Epilepsy Behav; 2018 Mar; 80():247-253. PubMed ID: 29433949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients' and physicians' perspectives on pharmacogenetic testing.
    Rogausch A; Prause D; Schallenberg A; Brockmöller J; Himmel W
    Pharmacogenomics; 2006 Jan; 7(1):49-59. PubMed ID: 16354124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valuing pharmacogenetic testing services: a comparison of patients' and health care professionals' preferences.
    Payne K; Fargher EA; Roberts SA; Tricker K; Elliott RA; Ratcliffe J; Newman WG
    Value Health; 2011 Jan; 14(1):121-34. PubMed ID: 21211494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eliciting patients' preferences for epilepsy diagnostics: a discrete choice experiment.
    Wijnen BF; de Kinderen RJ; Colon AJ; Dirksen CD; Essers BA; Hiligsmann M; Leijten FS; Ossenblok PP; Evers SM
    Epilepsy Behav; 2014 Feb; 31():102-9. PubMed ID: 24389020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients' Preferences for Artificial Intelligence Applications Versus Clinicians in Disease Diagnosis During the SARS-CoV-2 Pandemic in China: Discrete Choice Experiment.
    Liu T; Tsang W; Huang F; Lau OY; Chen Y; Sheng J; Guo Y; Akinwunmi B; Zhang CJ; Ming WK
    J Med Internet Res; 2021 Feb; 23(2):e22841. PubMed ID: 33493130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.
    Nevitt SJ; Marson AG; Tudur Smith C
    Cochrane Database Syst Rev; 2019 Jul; 7(7):CD001911. PubMed ID: 31318037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician and Patient Preferences for Nonvalvular Atrial Fibrillation Therapies.
    Shafrin J; Bruno A; MacEwan JP; Campinha-Bacote A; Trocio J; Shah M; Tan W; Romley JA
    Value Health; 2016 Jun; 19(4):451-9. PubMed ID: 27325337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HLA-B*15:02 polymorphism and Tegretol
    Chouchi M; Kaabachi W; Tizaoui K; Daghfous R; Aidli SE; Hila L
    Rev Neurol (Paris); 2018 May; 174(5):278-291. PubMed ID: 29685430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand.
    Rattanavipapong W; Koopitakkajorn T; Praditsitthikorn N; Mahasirimongkol S; Teerawattananon Y
    Epilepsia; 2013 Sep; 54(9):1628-38. PubMed ID: 23895569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating preferences and willingness to pay for pharmacogenetic testing in populations who are medically underserved: a discrete choice experiment.
    Gawronski BE; Salloum RG; Duarte JD
    Front Pharmacol; 2024; 15():1384667. PubMed ID: 38595920
    [No Abstract]   [Full Text] [Related]  

  • 15. Public preferences for pharmacogenetic testing in the NHS: Embedding a discrete choice experiment within service design to better meet user needs.
    McDermott JH; Sharma V; Newman WG; Wilson P; Payne K; Wright S
    Br J Clin Pharmacol; 2024 Jul; 90(7):1699-1710. PubMed ID: 38616172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring High-Risk Patients' Preferences for Pharmacogenetic Testing to Reduce Severe Adverse Drug Reaction: A Discrete Choice Experiment.
    Dong D; Ozdemir S; Mong Bee Y; Toh SA; Bilger M; Finkelstein E
    Value Health; 2016; 19(6):767-775. PubMed ID: 27712704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review.
    Nevitt SJ; Sudell M; Tudur Smith C; Marson AG
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012065. PubMed ID: 31233229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What influences persistence with medicines? A multinational discrete choice experiment of 2549 patients.
    Holmes EA; Morrison VL; Hughes DA
    Br J Clin Pharmacol; 2016 Aug; 82(2):522-31. PubMed ID: 27074550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy.
    Kim WJ; Lee JH; Yi J; Cho YJ; Heo K; Lee SH; Kim SW; Kim MK; Kim KH; In Lee B; Lee MG
    Pharmacogenet Genomics; 2010 Apr; 20(4):249-56. PubMed ID: 20216337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do no harm--but first we need to know more: the case of adverse drug reactions with antiepileptic drugs.
    Singh G
    Neurol India; 2011; 59(1):53-8. PubMed ID: 21339660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.